跳至主要内容
临床试验/JPRN-UMIN000010159
JPRN-UMIN000010159已完成未知

Effect of Haemodialysis on the Plasma glucose profile and Plasma level of Liraglutide in People with Type 2 Diabetes Mellitus and End Stage Renal Disease - Effect of Haemodialysis on the Plasma glucose profile and Plasma level of Liraglutide in People with Type 2 Diabetes Mellitus and End Stage Renal Disease

akakinen Clinic0 个研究点目标入组 10 人开始时间: 2013年3月8日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1-Type 1 Diabetes Mellitus 2-Previous treatment with other incretin mimetics within the previous three months before screening. 3-Insulin-requiring type 2 Diabetes Mellitus 4-Impaired hepatic function, measured as serum glutamic oxaloacetic transaminase [sGOT ( Aspartate Aminotransferase , ASAT)] or serum glutamic pyruvic transaminase (sGPT) ≥ 100 IU/L 5-Unstable cardiovascular or cerebrovascular disease. 6-Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures. 7-Female of childbearing potential who are not using adequate contraceptive menthods 8-Known or suspected allergy to trial medication(s), excipients, or related products. 9-Any contraindications to liraglutide.

研究者

发起方
akakinen Clinic

相似试验